Reproductive health
Uterine fibroids and the cost of silence
October 9, 2025Medical Communications, Research and Development Reproductive health, gynaecological conditions, menstruation, uterine fibroids
By Tina Backhouse Stigma and shame Every month, most women on the planet have a period. It’s completely natural – …
Universal Quantum partners with Open Quantum Institute to tackle endometriosis with new technology
July 29, 2025Medical Communications, Research and Development Open Quantum Institute, Pain, Reproductive health, UN Sustainable Development Goals, United Nations, Universal Quantum, endometriosis, women's health
Based in Brighton, UK, Universal Quantum has joined the Open Quantum Institute (OQI) to explore how quantum computing could revolutionise …
The Problem of Endometriosis in the UK
July 7, 2025Research and Development NHS, Obstetrics & Gynaecology, Pain, Reproductive health, Theramex, endometriosis, gynaecology
When did we decide it was an acceptable condition of womanhood in the UK to live with chronic pain?
Ferring strengthens evidence for flexible dosing of follitropin delta in IVF
July 3, 2025Research and Development Ferring Pharmaceuticals, IVF, Reproductive health, clinical trial, fertility treatment, in vitro fertilisation, ovarian hyperstimulation syndrome, pregnancy, reproductive health, reproductive medicine
Ferring Pharmaceuticals has reported that a conventional 15µg/day starting dose of follitropin delta (Rekovelle) provides comparable efficacy and safety to …
New hormonal treatment launched to help prevent miscarriage in early pregnancy
April 4, 2025Research and Development Besins Healthcare, Reproductive health, hormonal therapy, miscarriage, pregnancy
A new progesterone-based treatment aimed at preventing miscarriage has been launched across the UK, following a major clinical trial that …
Theramex receives recommendation for YSELTY in Scotland
November 11, 2024Research and Development Pain, Reproductive health, appproval, tumours, women's health
Theramex, a dedicated women’s health company, have announced that the Scottish Medicines Consortium (SMC) have recommended YSELTY (linzagolix) for the …
First oral treatment for hormone-sensitive prostate cancer recommended by NICE
August 15, 2024Research and Development Accord healthcare, Oncology, Reproductive health, hormone-sensitive, prostate cancer
Today, Accord Healthcare has announced that the National Institute for Health and Care excellence (NICE) have recommended the first oral …
US FDA expands Jemperli (dostarlimab-gxly) plus chemotherapy approval to all adult patients with primary advanced or recurrent endometrial cancer as the first and only immuno-oncology-based treatment to show an overall survival benefit
August 5, 2024Research and Development GSK, Oncology, Reproductive health, endometrial cancer
PHILADELPHIA–GSK plc today announced the US Food and Drug Administration (FDA) has approved Jemperli (dostarlimab-gxly) in combination with carboplatin and paclitaxel (chemotherapy) …
Oxolife shares data from phase 2 trial for infertility drug
July 8, 2024Research and Development Oxolife, Reproductive health, clinical trial, infertility
Oxolife has announced positive phase 2 clinical data on its fertility pill OXO-001 at the European Society of Human Reproduction …
GSK shares results from phase 3 trial for gonorrhoea treatment
April 18, 2024Research and Development GSK, Reproductive health, clinical trial, gonorrhoea, sexual health
GSK has announced positive results from its phase 3 EAGLE-1 trial for gepotidacin, a potential first-in-class oral antibiotic for the …
An overview of women’s health in 2024
April 9, 2024Reproductive health, abortion, fertility, reproductive health, women's health
Betsy Goodfellow from Pharmafocus considers the current landscape of women’s health, covering recent debates and ongoing issues within the reproductive health sphere …
J&J’s nipocalimab gains breakthrough therapy designation from FDA for HDFN treatment
February 12, 2024Medical Communications Breakthrough Therapy Designation, FDA, HDFN, J&J, Reproductive health
Johnson & Johnson (J&J) has announced that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) …
Latest content
FibroFind appoints Lee Borthwick as CEO
